240 related articles for article (PubMed ID: 30231378)
1. Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond.
Nishino M
Am Soc Clin Oncol Educ Book; 2018 May; 38():1019-1029. PubMed ID: 30231378
[TBL] [Abstract][Full Text] [Related]
2. Response criteria in oncologic imaging: review of traditional and new criteria.
Tirkes T; Hollar MA; Tann M; Kohli MD; Akisik F; Sandrasegaran K
Radiographics; 2013; 33(5):1323-41. PubMed ID: 24025927
[TBL] [Abstract][Full Text] [Related]
3. Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0.
Chalian H; Töre HG; Horowitz JM; Salem R; Miller FH; Yaghmai V
Radiographics; 2011; 31(7):2093-105. PubMed ID: 22084190
[TBL] [Abstract][Full Text] [Related]
4. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
5. Advances in oncological treatment: limitations of RECIST 1.1 criteria.
Grimaldi S; Terroir M; Caramella C
Q J Nucl Med Mol Imaging; 2018 Jun; 62(2):129-139. PubMed ID: 29166754
[TBL] [Abstract][Full Text] [Related]
6. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
[TBL] [Abstract][Full Text] [Related]
7. Radiologic measurements of tumor response to treatment: practical approaches and limitations.
Suzuki C; Jacobsson H; Hatschek T; Torkzad MR; Bodén K; Eriksson-Alm Y; Berg E; Fujii H; Kubo A; Blomqvist L
Radiographics; 2008; 28(2):329-44. PubMed ID: 18349443
[TBL] [Abstract][Full Text] [Related]
8. Response to treatment series: part 2, tumor response assessment--using new and conventional criteria.
Yaghmai V; Miller FH; Rezai P; Benson AB; Salem R
AJR Am J Roentgenol; 2011 Jul; 197(1):18-27. PubMed ID: 21701006
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Response and Progression to Immunotherapy.
Borcoman E; Nandikolla A; Long G; Goel S; Le Tourneau C
Am Soc Clin Oncol Educ Book; 2018 May; 38():169-178. PubMed ID: 30231380
[TBL] [Abstract][Full Text] [Related]
10. The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST.
Inno A; Lo Russo G; Salgarello M; Corrao G; Casolino R; Galli G; Modena A; Romano L; Pusceddu S; Greco FG; Garassino MC; Gori S
Tumori; 2018; 104(2):88-95. PubMed ID: 29714647
[TBL] [Abstract][Full Text] [Related]
11. Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy.
Barnacle AM; McHugh K
Pediatr Blood Cancer; 2006 Feb; 46(2):127-34. PubMed ID: 16231313
[TBL] [Abstract][Full Text] [Related]
12. Radiological monitoring of the treatment of solid tumors in practice.
Ganten MK; Ganten TM; Schlemmer HP
Rofo; 2014 May; 186(5):466-73. PubMed ID: 24563412
[TBL] [Abstract][Full Text] [Related]
13. Universes collide: combining immunotherapy with targeted therapy for cancer.
Wargo JA; Cooper ZA; Flaherty KT
Cancer Discov; 2014 Dec; 4(12):1377-86. PubMed ID: 25395294
[TBL] [Abstract][Full Text] [Related]
14. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
[TBL] [Abstract][Full Text] [Related]
15. A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors.
Lalchandani UR; Sahai V; Hersberger K; Francis IR; Wasnik AP
Curr Probl Diagn Radiol; 2019; 48(6):576-585. PubMed ID: 30181058
[TBL] [Abstract][Full Text] [Related]
16. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community.
Liu Y; Litière S; de Vries EG; Sargent D; Shankar L; Bogaerts J; Seymour L
Eur J Cancer; 2014 Jan; 50(2):260-6. PubMed ID: 24239447
[TBL] [Abstract][Full Text] [Related]
17. Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.
Socinski MA
Semin Oncol; 2015 Oct; 42 Suppl 2():S19-28. PubMed ID: 26477471
[TBL] [Abstract][Full Text] [Related]
18. iRECIST: how to do it.
Persigehl T; Lennartz S; Schwartz LH
Cancer Imaging; 2020 Jan; 20(1):2. PubMed ID: 31900236
[TBL] [Abstract][Full Text] [Related]
19. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
20. Complexity of Delivering Precision Medicine: Opportunities and Challenges.
Davis AA; McKee AE; Kibbe WA; Villaflor VM
Am Soc Clin Oncol Educ Book; 2018 May; 38():998-1007. PubMed ID: 30231318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
